In the past week, CABA stock has gone down by -11.86%, with a monthly decline of -16.58% and a quarterly surge of 12.64%. The volatility ratio for the week is 7.50%, and the volatility levels for the last 30 days are 10.76% for Cabaletta Bio Inc The simple moving average for the past 20 days is -18.47% for CABA’s stock, with a -38.36% simple moving average for the past 200 days.
Is It Worth Investing in Cabaletta Bio Inc (NASDAQ: CABA) Right Now?
The 36-month beta value for CABA is also noteworthy at 2.70. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for CABA is 81.83M, and at present, short sellers hold a 7.90% of that float. The average trading volume of CABA on July 02, 2025 was 2.01M shares.
CABA) stock’s latest price update
Cabaletta Bio Inc (NASDAQ: CABA) has seen a rise in its stock price by 2.63 in relation to its previous close of 1.52. However, the company has experienced a -11.86% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-11 that PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 10,800,000 shares of its common stock and accompanying warrants to purchase an aggregate of 10,800,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.00001 per pre-funded warrant. Cabaletta also granted the underwriters a 30-day option to purchase up to an additional 15,000,000 shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire fifteen months from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $2.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $1.99999.
Analysts’ Opinion of CABA
Many brokerage firms have already submitted their reports for CABA stocks, with Evercore ISI repeating the rating for CABA by listing it as a “In-line.” The predicted price for CABA in the upcoming period, according to Evercore ISI is $6 based on the research report published on December 20, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see CABA reach a price target of $6, previously predicting the price at $12. The rating they have provided for CABA stocks is “Equal Weight” according to the report published on December 19th, 2024.
UBS gave a rating of “Buy” to CABA, setting the target price at $10 in the report published on October 10th of the previous year.
CABA Trading at -6.49% from the 50-Day Moving Average
After a stumble in the market that brought CABA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.21% of loss for the given period.
Stock Fundamentals for CABA
The total capital return value is set at -1.02. Equity return is now at value -73.85, with -62.51 for asset returns.
Based on Cabaletta Bio Inc (CABA), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -3.3. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -295.7.
Currently, EBITDA for the company is -125.14 million with net debt to EBITDA at 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.96.
Conclusion
In summary, Cabaletta Bio Inc (CABA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
